Morgan Stanley maintains a "overweight" rating on GUSHENGTANG(02273) with a target price of 62 Hong Kong dollars.
Currently, private hospitals are not required to participate in volume-based procurement. The company expects the group to achieve a revenue growth of over 20% this year, with a profit increase of over 25%.
Morgan Stanley released a research report stating that they are maintaining a "buy" rating for GUSHENGTANG (02273) with a target price of 62 Hong Kong dollars. Currently, private hospitals are not required to participate in volume-based procurement. The bank expects the group to achieve revenue growth of over 20% this year, with profit growth expected to be over 25%.
Related Articles

Guosen: The final mindset of asset trend convergence.

Software crashed together? Roblox (RBLX.US): It has an ecological closed-loop, Genie can't break.

Industrial: Hong Kong stock market sentiment index has reached the bottom area.
Guosen: The final mindset of asset trend convergence.

Software crashed together? Roblox (RBLX.US): It has an ecological closed-loop, Genie can't break.

Industrial: Hong Kong stock market sentiment index has reached the bottom area.

RECOMMEND

Nine Companies With Market Value Over RMB 100 Billion Awaiting, Hong Kong IPO Boom Continues Into 2026
07/02/2026

Hong Kong IPO Cornerstone Investments Surge: HKD 18.52 Billion In First Month, Up More Than 13 Times Year‑On‑Year
07/02/2026

Over 400 Companies Lined Up For Hong Kong IPOs; HKEX Says Market Can Absorb
07/02/2026


